Cohance Lifesciences Ltd (COHANCE)

NSE · Healthcare · Pharmaceuticals & Biotechnology · Pharmaceuticals

₹444.30

As of 30 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close ₹444.30 on 30 Oct 2026. The share price traded between ₹266.70 and ₹779.45 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close ₹444.30

Low ₹266.70High ₹779.45

Market cap₹16,993 crorelast close × shares
P/E159.8on reported profit, last four quarters
Profit, last 12 months₹106 crto shareholders
Profit incl. minorities₹59 crlast 12 months
Return on equity4.9%year to Mar 2026
EBITDA margin19%year to Mar 2026
Debt to equity0.10year to Mar 2026
Net margin6.6%year to Mar 2026
Dividend yieldnonelast 12 months

Price trend

Revenue and profit

RevenueNet profit₹ crore
01,0002,0003,000
YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue1,3201,3401,0512,6082,269
Net profit454411300484150
EBITDA margin44%43%39%31%19%
Borrowings977065486400

₹ crore. Over three years, compounded: revenue grew 19.2% a year, net profit fell 28.5% a year.

Recent filings

Questions about Cohance Lifesciences Ltd

What is Cohance Lifesciences Ltd's market value?

Cohance Lifesciences Ltd's market value is ₹16,993 crore as of 30 Oct 2026 close: the last close times the shares in issue. Its P/E is 159.8, the last close over earnings per share for the last four reported quarters.

When are Cohance Lifesciences Ltd's next results?

Cohance Lifesciences Ltd's next results are listed for 6 Nov 2026 (the exchange's notice: Financial Results). Dates are as the company announced them, on the list of 30 Oct 2026.

Who are Cohance Lifesciences Ltd's largest named shareholders?

In the shareholding pattern for the quarter ended 30 Sep 2026, the largest named holders above 1% were: BEHRYANDA LIMITED (promoter group) 33.34%; JUSMIRAL HOLDINGS LIMITED (promoter group) 24.15%; JASUB PROPERTY HOLDINGS LLP (public) 3.84%. Percentages are of all shares.

Go further with COHANCE

Free to start: test a trading idea on COHANCE's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Pharmaceuticals), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

P/E 159.8 is the close over earnings per share, the profit that belongs to the company's shareholders (market cap divided by P/E: 106 crore for the last 12 months, shown above). The net profit including the share owned by minority shareholders of subsidiaries is 59 crore; market cap divided by that gives 288.0. The last 12 months are the four latest reported quarters, so their profit can differ from the newest year's in the table below.